Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | MDM2 | Q00987 | 5/20 | 0.49 |
| ▸ | TGM2 | P21980 | 5/20 | 0.49 |
| ▸ | TLR2 | O60603 | 2/20 | 0.48 |
| ▸ | MDM4 | O15151 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29400961 | 1.00 | KMT2A (0.57) | KMT2AMDM2TGM2TLR2MDM4 | |
| SCHEMBL178701 | 1.00 | KMT2A (0.57) | KMT2AMDM2TGM2TLR2MDM4 | |
| SCHEMBL29401249 | 1.00 | KMT2A (0.57) | KMT2AMDM2TGM2TLR2MDM4 | |
| SCHEMBL29391986 | 1.00 | KMT2A (0.57) | KMT2AMDM2TGM2TLR2MDM4 | |
| SCHEMBL29958970 | 1.00 | KMT2A (0.57) | KMT2AMDM2TGM2TLR2MDM4 | |
| SCHEMBL25358347 | 1.00 | KMT2A (0.57) | KMT2AMDM2TGM2TLR2MDM4 | |
| SCHEMBL29350360 | 1.00 | KMT2A (0.57) | KMT2AMDM2TGM2TLR2MDM4 | |
| SCHEMBL178771 | 1.00 | KMT2A (0.57) | KMT2AMDM2TGM2TLR2MDM4 | |
| SCHEMBL21462054 | 1.00 | KMT2A (0.57) | KMT2AMDM2TGM2TLR2MDM4 | |
| SCHEMBL25356530 | 0.99 | KMT2A (0.59) | KMT2AMDM2TGM2TLR2MDM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12371454-B2 | Cyclic peptide compound having Kras inhibitory action | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-07-29 | — | — | US | disclosed |
| US-20240400617-A1 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-12-05 | — | — | US | disclosed |
| WO-2024213022-A1 | INCRETIN ANALOGUES AND PREPARATION METHOD THEREFOR, AND APPLICATION | 上海多米瑞生物技术有限公司 | 2024-10-17 | — | — | WO | disclosed |
| US-20240148821-A1 | PHARMACEUTICAL USE OF CYCLIC PEPTIDE COMPOUND | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-05-09 | — | — | US | disclosed |
| EP-4316503-A1 | PHARMACEUTICAL USE OF CYCLIC PEPTIDE COMPOUND | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-02-07 | — | — | EP | disclosed |
| US-11674136-B2 | DNA-templated macrocycle library | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2023-06-13 | — | — | US | disclosed |
| US-20230151060-A1 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-05-18 | — | — | US | disclosed |
| CN-114763369-A | Aliphatic peptide chain and Fab-aliphatic chain conjugate | 正大天晴药业集团股份有限公司 | 2022-07-19 | — | — | CN | disclosed |
| CN-114106091-A | Protein analogs and conjugates thereof | 正大天晴药业集团股份有限公司 | 2022-03-01 | — | — | CN | disclosed |
| US-10988523-B2 | Modified lipidated Relaxin B chain peptides and their therapeutic use | SANOFI (FR) | 2021-04-27 | — | — | US | disclosed |
| US-20150259721-A1 | CELL LINES | ALLOZYNE, INC. | 2015-09-17 | — | — | US | disclosed |
| US-20080171783-A1 | COMPOSITIONS AND METHODS FOR TREATING HYPERPROLIFERATIVE DISEASE | MIGENIX INC. (CA) | 2008-07-17 | — | — | US | disclosed |
| WO-2008080223-A1 | COMPOSITIONS AND METHODS FOR TREATING HYPERPROLIFERATIVE DISEASE | MIGENIX INC. (CA) | 2008-07-10 | — | — | WO | disclosed |
| EP-1910279-A2 | NON-NUCLEOSIDE ANTI-HEPACIVIRUS AGENTS AND USES THEREOF | MIGENIX INC. (CA) | 2008-04-16 | — | — | EP | disclosed |
| EP-1718340-B1 | NEW EFFECTOR CONJUGATES, PROCESS FOR THEIR PRODUCTION AND THEIR PHARMACEUTICAL USE | BAYER SCHERING PHARMA AG (DE) | 2007-11-21 | — | — | EP | disclosed |
| US-20070021434-A1 | NON-NUCLEOSIDE ANTI-HEPACIVIRUS AGENTS AND USES THEREOF | MIGENIX INC. (CA) | 2007-01-25 | — | — | US | disclosed |
| WO-2007002639-A2 | NON-NUCLEOSIDE ANTI-HEPACIVIRUS AGENTS AND USES THEREOF | MIGENIX INC. (CA) | 2007-01-04 | — | — | WO | disclosed |
| EP-1718340-A2 | NEW EFFECTOR CONJUGATES, PROCESS FOR THEIR PRODUCTION AND THEIR PHARMACEUTICAL USE | Schering AG (DE) | 2006-11-08 | — | — | EP | disclosed |
| US-20050234247-A1 | New effector conjugates, process for their production and their pharmaceutical use | SCHERING AG (DE) | 2005-10-20 | — | — | US | disclosed |
| WO-2005074901-A2 | NEW EFFECTOR CONJUGATES, PROCESS FOR THEIR PRODUCTION AND THEIR PHARMACEUTICAL USE | SCHERING AG (DE) | 2005-08-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230151060-A1 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION | KRAS, NRAS, HRAS | KMT2A 3145/4885MDM2 164/4885TGM2 2830/4885 |
| US-11674136-B2 | DNA-templated macrocycle library | IDE, IAPP, POLRMT | KMT2A 3958/4885MDM2 938/4885TGM2 1572/4885 |
| US-20070021434-A1 | NON-NUCLEOSIDE ANTI-HEPACIVIRUS AGENTS AND USES THEREOF | HAVCR2, ADAR, NSUN2 | KMT2A 3406/4885MDM2 3730/4885TGM2 393/4885 |
| US-20240400617-A1 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION | KRAS, NRAS, HRAS | KMT2A 3145/4885MDM2 164/4885TGM2 2830/4885 |
| US-20150259721-A1 | CELL LINES | AARS1, LARS1, IARS1 | KMT2A 1119/4885MDM2 2899/4885TGM2 942/4885 |
| US-10988523-B2 | Modified lipidated Relaxin B chain peptides and their therapeutic use | RXFP1, RXFP2, SCTR | KMT2A 3508/4885MDM2 4880/4885TGM2 1186/4885 |
| US-20050234247-A1 | New effector conjugates, process for their production and their pharmaceutical use | EPOR, TIE1, TEK | KMT2A 3816/4885MDM2 1955/4885TGM2 2091/4885 |
| US-20080171783-A1 | COMPOSITIONS AND METHODS FOR TREATING HYPERPROLIFERATIVE DISEASE | POLQ, POLI, POLH | KMT2A 1805/4885MDM2 2451/4885TGM2 611/4885 |
| US-20240148821-A1 | PHARMACEUTICAL USE OF CYCLIC PEPTIDE COMPOUND | VIP, IAPP, KRAS | KMT2A 4757/4885MDM2 1604/4885TGM2 4152/4885 |
| US-12371454-B2 | Cyclic peptide compound having Kras inhibitory action | KRAS, NRAS, HRAS | KMT2A 3145/4885MDM2 164/4885TGM2 2830/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.